Literature DB >> 27726016

Adjuvant post-operative I-131 therapy in differentiated thyroid carcinoma: are the 2015 ATA guidelines an exact science or a dark art?

Frederik A Verburg1, Markus Luster2, Luca Giovanella3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27726016     DOI： 10.1007/s00259-016-3526-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  9 in total

1.  Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer.

Authors:  Frederik A Verburg; Cumali Aktolun; Arturo Chiti; Savvas Frangos; Luca Giovanella; Martha Hoffmann; Ioannis Iakovou; Jasna Mihailovic; Bernd J Krause; Werner Langsteger; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-17       Impact factor: 9.236

2.  Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid.

Authors:  S M SEIDLIN; L D MARINELLI; E OSHRY
Journal:  J Am Med Assoc       Date:  1946-12-07

3.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

Review 4.  Papillary and follicular thyroid carcinoma.

Authors:  M J Schlumberger
Journal:  N Engl J Med       Date:  1998-01-29       Impact factor: 91.245

Review 5.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

6.  Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients.

Authors:  Ian D Hay; Geoffrey B Thompson; Clive S Grant; Eric J Bergstralh; Catherine E Dvorak; Colum A Gorman; Megan S Maurer; Bryan McIver; Brian P Mullan; Ann L Oberg; Claudia C Powell; Jon A van Heerden; John R Goellner
Journal:  World J Surg       Date:  2002-05-21       Impact factor: 3.352

7.  Guidelines for radioiodine therapy of differentiated thyroid cancer.

Authors:  M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

8.  Life expectancy is reduced in differentiated thyroid cancer patients ≥ 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients.

Authors:  Frederik A Verburg; Uwe Mäder; Karina Tanase; Elena-Daphne Thies; Stefanie Diessl; Andreas K Buck; Markus Luster; Christoph Reiners
Journal:  J Clin Endocrinol Metab       Date:  2012-11-12       Impact factor: 5.958

9.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965
  9 in total
  4 in total

1.  Guidelines Are Not Gospel!

Authors:  Gilbert H Daniels; Peter A Kopp
Journal:  Thyroid       Date:  2019-06       Impact factor: 6.568

Review 2.  Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?

Authors:  Dagmara Rusinek; Ewa Chmielik; Jolanta Krajewska; Michal Jarzab; Malgorzata Oczko-Wojciechowska; Agnieszka Czarniecka; Barbara Jarzab
Journal:  Int J Mol Sci       Date:  2017-08-22       Impact factor: 5.923

3.  Therapeutic Strategy in Low-Risk Papillary Thyroid Carcinoma - Long-Term Results of the First Single-Center Prospective Non-Randomized Trial Between 2011 and 2015.

Authors:  Agnieszka Czarniecka; Marcin Zeman; Grzegorz Wozniak; Adam Maciejewski; Ewa Stobiecka; Ewa Chmielik; Malgorzata Oczko-Wojciechowska; Jolanta Krajewska; Daria Handkiewicz-Junak; Barbara Jarzab
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-06       Impact factor: 5.555

4.  Evaluation of the 2015 ATA Guidelines in Patients With Distant Metastatic Differentiated Thyroid Cancer.

Authors:  Evert F S van Velsen; Merel T Stegenga; Folkert J van Kemenade; Boen L R Kam; Tessa M van Ginhoven; W Edward Visser; Robin P Peeters
Journal:  J Clin Endocrinol Metab       Date:  2020-03-01       Impact factor: 5.958
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.